Optimal primary end point in Phase II trials of immune checkpoint inhibitors for advanced solid cancers: An evolving issue
Roviello G.
•
•
Ianza A.
2019
Periodico
IMMUNOTHERAPY
Abstract
N/A
DOI
WOS
Archivio
Diritti
open access
license:digital rights management non definito
license:digital rights management non definito
license uri:iris.pri00
license uri:iris.pri00
FVG url
Soggetti